United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Takes Position in Hologic, Inc. (NASDAQ:HOLX)

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund purchased a new position in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 9,700 shares of the medical equipment provider's stock, valued at approximately $699,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HOLX. FMR LLC increased its holdings in shares of Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider's stock worth $453,940,000 after acquiring an additional 2,174,093 shares during the period. Boston Partners increased its position in shares of Hologic by 81.0% during the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock valued at $257,959,000 after purchasing an additional 1,602,463 shares during the period. Nordea Investment Management AB raised its holdings in shares of Hologic by 32.7% in the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider's stock worth $159,911,000 after purchasing an additional 544,889 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Hologic during the 4th quarter valued at $27,007,000. Finally, Teacher Retirement System of Texas raised its position in shares of Hologic by 82.9% during the fourth quarter. Teacher Retirement System of Texas now owns 649,883 shares of the medical equipment provider's stock worth $46,850,000 after purchasing an additional 294,538 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Remove Ads

Hologic Stock Down 1.6 %

Shares of HOLX traded down $1.00 during trading hours on Friday, hitting $61.32. 1,110,999 shares of the company were exchanged, compared to its average volume of 1,809,690. The firm's 50 day moving average is $65.24 and its 200-day moving average is $73.29. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a 52 week low of $60.34 and a 52 week high of $84.67. The company has a market cap of $13.76 billion, a PE ratio of 19.34, a PEG ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on HOLX shares. Citigroup dropped their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Royal Bank of Canada cut their price target on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a report on Thursday, February 6th. Leerink Partners lowered shares of Hologic from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. Wolfe Research started coverage on shares of Hologic in a research note on Friday, December 13th. They set a "peer perform" rating on the stock. Finally, Needham & Company LLC cut Hologic from a "buy" rating to a "hold" rating and set a $90.00 target price for the company. in a research report on Monday, February 3rd. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.